Advances in the treatment of Kawasaki disease

Current Opinion in Pediatrics

Volumn 25, Issue 1, 2013, Pages 103-109

  Dominguez, Samuel R ^a   Anderson, Marsha S ^a  

^a Children's Hospital Colorado   (United States)

Author keywords

infliximab; IVIG resistant; Kawasaki disease; steroids; therapy

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; CYCLOSPORIN A; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ULINASTATIN;

ADD ON THERAPY; CORONARY ARTERY ANEURYSM; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EARLY DIAGNOSIS; FEVER; HIGH RISK PATIENT; HUMAN; IMMUNOTHERAPY; JAPAN; MUCOCUTANEOUS LYMPH NODE SYNDROME; PATIENT IDENTIFICATION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; TREATMENT RESPONSE; UNITED STATES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ASPIRIN; CHILD; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MUCOCUTANEOUS LYMPH NODE SYNDROME; TREATMENT FAILURE;

EID: 84873079562     PISSN: 10408703     EISSN: 1531698X     Source Type: Journal    
DOI: 10.1097/MOP.0b013e32835c1122     Document Type: Review

References (68)

1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children [in Japanese]. Arerugi 1967; 16:178-222
2. Burns JC, Glode MP. Kawasaki syndrome. Lancet 2004; 364:533-544
3. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-Term management of Kawasaki disease: A statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004; 114:1708-1733
4. Furusho K, Kamiya T, Nakano H, et al. High-Dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984; 2:1055-1058
5. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med 1986; 315:341-347
6. Newburger JW, Takahashi M, Beiser AS, et al A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med 1991; 324:1633-1639
7. Kato H, Koike S, Yokoyama T. Kawasaki disease: Effect of treatment on coronary artery involvement. Pediatrics 1979; 63:175-179
8. Shinohara M, Sone K, Tomomasa T, et al. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr 1999; 135:465-469
9. Inoue Y, Okada Y, Shinohara M, et al A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: Clinical course and coronary artery outcome. J Pediatr 2006; 149:336-341
10. Sundel RP, Baker AL, Fulton DR, et al. Corticosteroids in the initial treatment of Kawasaki disease: Report of a randomized trial. J Pediatr 2003; 142:611-616
11. Wooditch AC, Aronoff SC. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: A meta-Analysis of 862 children. Pediatrics 2005; 116:989-995
12. Athappan G, Gale S, Ponniah T. Corticosteroid therapy for primary treatment of Kawasaki disease - weight of evidence: A meta-Analysis and systematic review of the literature. Cardiovasc J Afr 2009; 20:233-236
13. Newburger JW, Sleeper LA, McCrindle BW, et al. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease. N Engl J Med 2007; 356:663-675
14. Ogata S, Ogihara Y, Honda T, et al. Corticosteroid pulse combination therapy for refractory Kawasaki disease: A randomized trial. Pediatrics 2012; 129:e17-e23
15. Kobayashi T, Saji T, Otani T, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): A randomised, open-label, blinded-endpoints trial. Lancet 2012; 379:1613-1620
16. Son MB, Newburger JW. Management of Kawasaki disease: Corticosteroids revisited. Lancet 2012; 379:1571-1572
17. Song D, Yeo Y, Ha K, et al. Risk factors for Kawasaki disease-Associated coronary abnormalities differ depending on age. Eur J Pediatr 2009; 168:1315-1321
18. Belay ED, Maddox RA, Holman RC, et al. Kawasaki syndrome and risk factors for coronary artery abnormalities: United States. Pediatr Infect Dis J 2006; 25:245-249
19. Sudo D, Monobe Y, Yashiro M, et al. Case-control study of giant coronary aneurysms due to Kawasaki disease: The 19th nationwide survey. Pediatr Int 2010; 52:790-794
20. Kim T, Choi W, Woo CW, et al. Predictive risk factors for coronary artery abnormalities in Kawasaki disease. Eur J Pediatr 2007; 166:421-425
21. Son MB, Gauvreau K, Ma L, et al. Treatment of Kawasaki disease: Analysis of 27 US pediatric hospitals from 2001 to 2006. Pediatrics 2009; 124:1-8
22. Honkanen VE, McCrindle BW, Laxer RM, et al. Clinical relevance of the risk factors for coronary artery inflammation in Kawasaki disease. Pediatr Cardiol 2003; 24:122-126
23. Sabharwal T, Manlhiot C, Benseler SM, et al. Comparison of factors associated with coronary artery dilation only versus coronary artery aneurysms in patients with Kawasaki disease. Am J Cardiol 2009; 104:1743-1747
24. Beiser AS, Takahashi M, Baker AL, et al A predictive instrument for coronary artery aneurysms in Kawasaki disease. US Multicenter Kawasaki Disease Study Group. Am J Cardiol 1998; 81:1116-1120
25. McCrindle BW, Li JS, Minich LL, et al. Coronary artery involvement in children with Kawasaki disease: Risk factors from analysis of serial normalized measurements. Circulation 2007; 116:174-179
26. Kobayashi T, Inoue Y, Takeuchi K, et al. Prediction of intravenous immunoglobulin unresponsiveness in patients with Kawasaki disease. Circulation 2006; 113:2606-2612
27. Sano T, Kurotobi S, Matsuzaki K, et al. Prediction of nonresponsiveness to standard high-Dose gamma-globulin therapy in patients with acute Kawasaki disease before starting initial treatment. Eur J Pediatr 2007; 166:131-137
28. Egami K, Muta H, Ishii M, et al. Prediction of resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2006; 149:237-240
29. Sleeper LA, Minich LL, McCrindle BM, et al. Evaluation of Kawasaki disease risk-scoring systems for intravenous immunoglobulin resistance. J Pediatr 2011; 158:831.e3-835.e3
30. Tremoulet AH, Best BM, Song S, et al. Resistance to intravenous immunoglobulin in children with Kawasaki disease. J Pediatr 2008; 153:117-121
31. Dominguez SR, Anderson MS, Eladawy M, et al. Preventing coronary artery abnormalities: A need for earlier diagnosis and treatment of Kawasaki disease. Pediatr Infect Dis J 2012; 31:1217-1220
32. Knight DM, Trinh H, Le J, et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993; 30:1443-1453
33. Matsubara T, Furukawa S, Yabuta K. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-Artery lesions. Clin Immunol Immunopathol 1990; 56:29-36
34. Burns JC, Mason WH, Hauger SB, et al. Infliximab treatment for refractory Kawasaki syndrome. J Pediatr 2005; 146:662-667
35. Girish M, Subramaniam G. Infliximab treatment in refractory Kawasaki syndrome. Indian J Pediatr 2008; 75:521-522
36. O'Connor MJ, Saulsbury FT. Incomplete and atypical Kawasaki disease in a young infant: Severe, recalcitrant disease responsive to infliximab. Clin Pediatr (Phila) 2007; 46:345-348
37. Oishi T, Fujieda M, Shiraishi T, et al. Infliximab treatment for refractory Kawasaki disease with coronary artery aneurysm. Circ J 2008; 72:850-852
38. Weiss JE, Eberhard BA, Chowdhury D, et al. Infliximab as a novel therapy for refractory Kawasaki disease. J Rheumatol 2004; 31:808-810
39. Burns JC, Best BM, Mejias A, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2008; 153:833-838
40. Song MS, Lee SB, Sohn S, et al. Infliximab treatment for refractory Kawasaki disease in korean children. Korean Circ J 2010; 40:334-338
41. Mori M, Imagawa T, Hara R, et al. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: Report of an open-label case series. J Rheumatol 2012; 39:864-867
42. Son MB, Gauvreau K, Burns JC, et al. Infliximab for intravenous immunoglobulin resistance in Kawasaki disease: A retrospective study. J Pediatr 2011; 158:644.e1-649.e1
43. Choueiter NF, Olson AK, Shen DD, et al. Prospective open-label trial of etanercept as adjunctive therapy for kawasaki disease. J Pediatr 2010; 157:960.e1-966.e1
44. Portman MA, Olson A, Soriano B, et al. Etanercept as adjunctive treatment for acute Kawasaki disease: Study design and rationale. Am Heart J 2011; 161:494-499
45. Chi H, Huang FY, Chen MR, et al. ITPKC gene SNP rs28493229 and Kawasaki disease in Taiwanese children. Hum Mol Genet 2010; 19:1147-1151
46. Kuo HC, Yang KD, Juo SH, et al. ITPKC single nucleotide polymorphism associated with the Kawasaki disease in a Taiwanese population. PLoS One 2011; 6:e17370
47. Lin MT, Wang JK, Yeh JI, et al. Clinical implication of the C allele of the ITPKC gene SNP rs28493229 in Kawasaki disease: Association with disease susceptibility and BCG scar reactivation. Pediatr Infect Dis J 2011; 30:148-152
48. Onouchi Y, Gunji T, Burns JC, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet 2008; 40:35-42
49. Onouchi Y, Suzuki Y, Suzuki H, et al. ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease. Pharmacogenomics J 2011. doi: 10.1038/tpj.2011.45. [Epub ahead of print
50. Peng Q, Chen C, Zhang Y, et al. Single-nucleotide polymorphism rs2290692 in the 30 UTR of ITPKC associated with susceptibility to Kawasaki disease in a Han Chinese population. Pediatr Cardiol 2012; 33:1046-1053
51. Peng Q, Chen CH, Wu Q, et al. Association study of a functional SNP rs28493229 of ITPKC gene and Kawasaki disease in a Chinese population [in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2011; 28:644-648
52. Brogan PA, Shah V, Clarke LA, et al. T cell activation profiles in Kawasaki syndrome. Clin Exp Immunol 2008; 151:267-274
53. Franco A, Shimizu C, Tremoulet AH, et al. Memory T-cells and characterization of peripheral T-cell clones in acute Kawasaki disease. Autoimmunity 2010; 43:317-324
54. Suzuki H, Suenaga T, Takeuchi T, et al. Marker of T-cell activation is elevated in refractory Kawasaki disease. Pediatr Int 2010; 52:785-789
55. De Inocencio J, Hirsch R. The role of T cells in Kawasaki disease. Crit Rev Immunol 1995; 15:349-357
56. Brown TJ, Crawford SE, Cornwall ML, et al. CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J Infect Dis 2001; 184:940-943
57. Suzuki H, Terai M, Hamada H, et al. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J 2011; 30:871-876
58. Tremoulet AH, Pancoast P, Franco A, et al. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2012; 161:506-512
59. Ahn SY, Kim DS. Treatment of intravenous immunoglobulin-resistant Kawasaki disease with methotrexate. Scand J Rheumatol 2005; 34:136-139
60. Lee MS, An SY, Jang GC, et al A case of intravenous immunoglobulinresistant Kawasaki disease treated with methotrexate. Yonsei Med J 2002; 43:527-532
61. Lee TJ, Kim KH, Chun JK, et al. Low-Dose methotrexate therapy for intravenous immunoglobulin-resistant Kawasaki disease. Yonsei Med J 2008; 49:714-718
62. Harada T, Ito S, Shiga K, et al A report of two cases of Kawasaki disease treated with plasma exchange. Ther Apher Dial 2008; 12:176-179
63. Hokosaki T, Mori M, Nishizawa T, et al. Long-Term efficacy of plasma exchange treatment for refractory Kawasaki disease. Pediatr Int 2012; 54: 99-103
64. Imagawa T, Mori M, Miyamae T, et al. Plasma exchange for refractory Kawasaki disease. Eur J Pediatr 2004; 163:263-264
65. Kashiwagi Y, Kawashima H, Akamatsu N, et al. Efficacy of plasma exchange therapy for Kawasaki disease by cytokine profiling. Ther Apher Dial 2012; 16:281-283
66. Mori M, Imagawa T, Katakura S, et al. Efficacy of plasma exchange therapy for Kawasaki disease intractable to intravenous gamma-globulin. Mod Rheumatol 2004; 14:43-47
67. Iwashima S, Seguchi M, Matubayashi T, et al. Ulinastatin therapy in kawasaki disease. Clin Drug Investig 2007; 27:691-696
68. Kanai T, Ishiwata T, Kobayashi T, et al. Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: A retrospective study. Circulation 2011; 124:2822-2828